Kiromic Biopharma, Inc. (61) | Business Operations (7)
Browse by Subcategory
Recent Contracts
-
Indemnification Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark
(Filed With SEC on February 16, 2022)
-
Form of Director Services Agreement, to be effective upon initial public offering, between Kiromic BioPharma, Inc. and all independent directors
(Filed With SEC on June 26, 2020)
-
Voting Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc., certain investors and certain stockholders
(Filed With SEC on May 11, 2020)
-
Collaboration Agreement, dated February 4, 2019, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc
(Filed With SEC on May 11, 2020)
-
Indemnification Agreement effective as of January 27, 2022 by and between Kiromic BioPharma, Inc. and Pietro Bersani
(Filed With SEC on February 2, 2022)
-
Form of Director Indemnification Agreement, to be effective upon initial public offering, between Kiromic BioPharma, Inc. and all independent directors
(Filed With SEC on June 26, 2020)
-
Collaboration Agreement, dated February 6, 2020, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc
(Filed With SEC on May 11, 2020)